The generic name for Prevymis is letermovir [1].
What is letermovir used for?
Letermovir is a medication used for the prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult recipients of an allogeneic stem cell transplant who are CMV-seropositive [1].
How does letermovir work?
Letermovir is a viral DNA terminase inhibitor. It works by inhibiting the enzyme complex responsible for cleaving and packaging the viral DNA into new virions, thereby preventing the replication of CMV [1].
When does letermovir's patent expire?
Information regarding the specific patent expiry dates for letermovir can be found through resources like DrugPatentWatch.com [2]. Patent protection is crucial for pharmaceutical companies to recoup research and development costs.
Who makes letermovir?
Prevymis, containing letermovir, is developed and marketed by Merck & Co. [1].
What are the side effects of letermovir?
Common side effects associated with letermovir include diarrhea, nausea, and vomiting [1].
Are there alternative CMV prevention methods for transplant patients?
Other strategies for CMV prevention in transplant recipients may include antiviral medications like ganciclovir or valganciclovir, or monitoring for CMV reactivation followed by preemptive treatment. The choice of prophylaxis or treatment depends on the patient's individual risk factors, the specific transplant type, and clinical guidelines [3].
---
Sources:
1. https://www.prevymis.com/
2. https://drugpatentwatch.com/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552179/